Hepatosplenic lymphoma presenting initially as hemophagocytic syndrome in a 21-year-old man with Crohn's disease: A case report and brief literature review

Canadian Journal of Gastroenterology

Volumn 25, Issue 8, 2011, Pages 417-418

  Côté Daigneault, Justin ^a   Bernard, Edmond Jean ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DEXAMETHASONE; ETOPOSIDE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; HEMOPHAGOCYTIC SYNDROME; HEPATOSPLENIC LYMPHOMA; HEPATOSPLENOMEGALY; HUMAN; LEUKOCYTE COUNT; LYMPHOMA; MALE; MULTIPLE ORGAN FAILURE; PANCYTOPENIA; PRIORITY JOURNAL; SEPTIC SHOCK; SPLENECTOMY; THROMBOCYTE COUNT; EPSTEIN BARR VIRUS INFECTION; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; LIVER TUMOR; PATHOLOGY; REVIEW; SPLEEN TUMOR; T CELL LYMPHOMA;

CROHN DISEASE; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; LIVER NEOPLASMS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; LYMPHOMA, T-CELL; MALE; SPLENIC NEOPLASMS; YOUNG ADULT;

EID: 80053324424     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2011/148927     Document Type: Article

References (10)

1. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
2. Sokol H, Seksik P, Carrat F, et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010;59:1363-8.
3. Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J. Lymphomas in rheumatoid arthritis patients treated with methotrexate: A 3-year prospective study in France. Blood 2002;99:3909-15. (Pubitemid 35332027)
4. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study. Lancet 2009;374:1617-25.
5. Peyrin-Biroulet L, Deltenre P, Suray N de, Branche J, Sandborn WJ, Colombel J-F. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644-53. (Pubitemid 351783447)
6. Siegel CA, Marden SM, Persing SM, Larson RJ. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: A meta-analysis. Clin Gastroenterol 2010;7:874-81.
7. Ochenrider MG, Patterson DJ, Aboulafia DM. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: Case report and literature review. Clin Lymphoma Myeloma Leuk 2010;10:144-8.
8. Falchook GS, Vega F, Dang NH, et al. Hepatosplenic gamma-delta T-cell lymphoma: Clinicopathological features and treatment. Ann Oncol 2009;20:1080-5.
9. Egeler RM, Webb D, Winiarski J, Janka G. HLH-2004: Diagnostic and Therapeutic Guidelines for Hemophagocytic Lymphohistiocytosis. ReVision. 2007;(February 2006):124-31.
10. N'guyen Y, Andreoletti L, Patey M, et al. Fatal Epstein-Barr virus primo infection in a 25-year-old man treated with azathioprine for Crohn's disease. J Clin Microbiol 2009;47:1252-4.